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Abstract
Objective
The objective of this study was to evaluate a quantitative method based on conventional T1-
weighted magnetic resonance (MR) imaging to assess fatty muscular degeneration in
patients with late-onset Pompe disease and to compare it with semi-quantitative visual eval-
uation (the Mercuri score). In addition, a long-term retrospective data analysis was per-
formed to evaluate treatment response to enzyme replacement therapy with alglucosidase
alfa.
Methods
MR images of the lumbar spine were acquired in 41 patients diagnosed with late-onset
Pompe disease from 2006 through 2015. Two independent readers retrospectively evalu-
ated fatty degeneration of the psoas and paraspinal muscles by applying the Mercuri score.
Quantitative semi-automated muscle and fat tissue separation was performed, and inter-
observer agreement and correlations with clinical parameters were assessed. Follow-up
examinations were performed in 13 patients treated with alglucosidase alfa after a median
of 39 months; in 7/13 patients, an additional follow-up examination was completed after a
median of 63 months.
Results
Inter-observer agreement was high. Measurements derived from the quantitative method
correlated well with Medical Research Council scores of muscle strength, with moderate
PLOS ONE | https://doi.org/10.1371/journal.pone.0190784 January 9, 2018 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Lollert A, Stihl C, Ho¨tker AM, Mengel E,
Ko¨nig J, Laudemann K, et al. (2018) Quantification
of intramuscular fat in patients with late-onset
Pompe disease by conventional magnetic
resonance imaging for the long-term follow-up of
enzyme replacement therapy. PLoS ONE 13(1):
e0190784. https://doi.org/10.1371/journal.
pone.0190784
Editor: Andrea Dardis, Azienda Ospedaliero-
Universitaria Santa Maria della Misericordia, ITALY
Received: August 15, 2017
Accepted: December 20, 2017
Published: January 9, 2018
Copyright: © 2018 Lollert et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was funded by Sanofi-
Genzyme (grant number LSD0136-2015) to GS.
The funder had no role in study design, data
collection and analysis, or preparation of the
manuscript.
correlations found for the 6-minute walk test, the 4-step stair climb test, and spirometry in
the supine position. A significant increase in the MR-derived fat fraction of the psoas muscle
was found between baseline and follow-up 1 (P = 0.016), as was a significant decrease in
the performance on the 6-minute walk test (P = 0.006) and 4-step stair climb test (P =
0.034), as well as plasma creatine kinase (P = 0.016). No statistically significant difference
in clinical or MR-derived parameters was found between follow-up 1 and follow-up 2.
Conclusions
Quantification of fatty muscle degeneration using the semi-automated method can provide
a more detailed overview of disease progression than semi-quantitative Mercuri scoring.
MR-derived data correlated with clinical symptoms and patient exercise capacity. After an
initial worsening, the fat fraction of the psoas muscle and performance on the 6-minute walk
test stayed constant during long-term follow-up under enzyme replacement therapy.
Introduction
Late-onset Pompe disease (LOPD) is a rare, inherited, autosomal-recessive condition, charac-
terized by a lack of lysosomal acid alpha glycosidase. This enzyme deficiency results in the
intralysosomal accumulation of glycogen in multiple body tissues, including skeletal muscle
[1]. Although the pathophysiology of muscle damage is not yet completely understood, lyso-
somal enlargement and rupture, as well as dysfunctional autophagy, lead to replacement of
muscle tissue by fat [2]. Patients clinically present with progressive proximal weakness, partic-
ularly of their trunk and limb muscles, and respiratory insufficiency or failure [3]. Though less
frequently assessed in the literature, the trunk muscles are highly relevant to characterizing the
disease. In fact, these muscles were identified in a recent electromyogram-based study having
the most frequent pathologies [4]. In contrast with patients who have infantile-onset Pompe
disease with mortality during the first year of life in most cases, patients with LOPD are usually
diagnosed during adolescence or adulthood, and present with a much slower disease progres-
sion [1]. Nevertheless, both populations can benefit from treatment.
Modern treatments for LOPD include enzyme replacement therapy (ERT) using recombi-
nant alglucosidase alfa, which can stabilize or delay muscular degeneration [5,6]. Treatment
efficacy is primarily monitored using clinical strength tests and pulmonary function tests [5,7].
Although morphologic changes in the musculature can be evaluated invasively by biopsy, non-
invasive imaging also has the potential, particularly during follow-up, to provide a more accu-
rate and objective clinical evaluation, and to identify clinically silent changes in the muscula-
ture [8].
These changes can be assessed by computed tomography [9] but the downside to this
approach is the need for ionizing radiation. The current clinical standard for evaluating the
extent of fatty muscle degeneration is to use magnetic resonance imaging (MRI) [10,11]. In the
past, a visual, semi-quantitative scoring system [12] (the Mercuri score) was applied to stan-
dard T1-weighted spin echo sequences [13] to assess fatty muscle degeneration. This score is
visually applied by the radiologist and ranges from 1 (normal muscle appearance) to 4 (severe
involvement, more than 60% fatty degeneration). More recently, new MRI techniques have
been developed to separate water and fat signals [14]. Dixon (water-/fat-) sequences have been
used to quantify fatty muscle infiltration in LOPD patients [15], with a significant advantage
Follow-up of patients with late-onset Pompe disease by conventional magnetic resonance imaging
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being their robustness against B0-/B1-inhomogeneities of the magnetic field. Another promis-
ing technique is proton-density measurement of the fat fraction (FF) [16], but this technique
has not yet been used for the assessment of LOPD patients. These techniques are appropriate
for the monitoring of contemporary and future cases, but older MRI data may comprise only
conventional spin echo (SE) sequences, complicating their comparison with recent data.
The assessment of fatty muscle degeneration by MRI using grayscale values based on signal
intensity has been reported using T1-weighted images [17]. Another group recently intro-
duced a quantification method based on signal intensity measurements of the paraspinal mus-
cles in relation to a small encircled area of subcutaneous fat from the same level [18]. A semi-
automated quantitative approach based on T2-weighted SE sequences has also been proposed
for the evaluation of fatty degeneration of paraspinal muscles [19], but this method has not yet
been applied on muscle degeneration arising from metabolic disorders.
Tthe purpose of this study therefore was to evaluate inter-observer agreement of this latter
quantitative method based on conventional T1-weighted MRI for the assessment of fatty mus-
cular degeneration in patients with LOPD compared with Mercuri scores. We also assessed
correlations with clinical parameters, and used the proposed quantitative method to evaluate
long-term follow-up under ERT.
Materials and methods
Patients
Initial MR evaluation. The initial MRI examinations of 41 patients (22 men, 19 women,
median age: 28 years, range: 6–74 years) with confirmed LOPD presenting at the metabolic
diseases clinic (“Villa Metabolica”) of the Medical Center of the Johannes Gutenberg Univer-
sity, Mainz, Germany, between 2006 and 2015 were analyzed in this retrospective single-center
study. All patients provided written informed consent to the MRI examination and data evalu-
ation. Approval by the local independent ethics committee was waived because of the retro-
spective study design.
Follow-up under ERT. Follow-up MRI examinations were available in 21 patients. Of
these, one patient was excluded because the follow-up examination was less than 24 months
after the initial MRI; five more patients were excluded because ERT was not initiated at all
(n = 1; this patient was evaluated separately to demonstrate natural disease progression), no
information concerning ERT could be retrieved from the medical record (n = 3), or ERT was
initiated more than 24 months after the baseline MRI (n = 1). Two more patients were
excluded, because ERT had been initiated one and two years prior to the first MRI examina-
tion. The remaining 13 patients were eligible for the assessment of long-term follow-up under
ERT. Detailed characteristics of these patients are shown in S1 Table. All patients were treated
according to a standardized scheme with 20 mg alglucosidase alfa (Myozyme1, Sanofi-Gen-
zyme) per kilogram of body weight every 2 weeks. The first follow-up MRI was performed at a
median of 39 months (range 24 to 50 months) after the baseline examinations. Seven patients
had a second follow-up MRI at a median of 63 months (range 50 to 83 months) after the initial
examination.
Muscle MRI
Examinations were performed using 1.5 T (Magnetom Avanto1, Siemens, Erlangen, Ger-
many; 45 mT/min, slew rate = 200 T/m/ms, n = 51) or 3T (Magnetom Skyra1, Siemens,
Erlangen, Germany; 45 mT/min, slew rate = 200 T/m/ms, n = 14) systems. The integrated
spine array coil was used for signal detection.
Follow-up of patients with late-onset Pompe disease by conventional magnetic resonance imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0190784 January 9, 2018 3 / 15
The imaging protocol consisted of T1-weighted turbo spin echo (TSE) sequences of the
lumbar spine in the coronal and transverse orientations. All sequences were acquired using a
reconstruction matrix of 384x384, a slice thickness of 5 mm, and a flip angle of 150˚. Other
scan parameters at 1.5 T were as follows: repetition time / echo time (TR/TE) 600/12 ms, echo
train length (ETL) 4, and field of view (FoV) 280 mm; at 3T these parameters were as follows:
TR/TE 630/11 ms, ETL 2, and FoV 200 mm.
Semi-quantitative evaluation of imaging data (the Mercuri score)
Two radiologists (respectively with 6 and 8 years of experience in MRI reading) independently
evaluated imaging data. Mercuri scores [12] were determined to visually assess the extent of
fatty degeneration of the psoas and paraspinal muscles.
Quantitative semi-automated evaluation
All measurements were performed by two independent observers using freely available image
analysis software (ImageJ, version 1.49; U.S. National Institutes of Health, Bethesda, Maryland,
USA; http://rsb.info.nih.gov/ij). Bilateral regions of interest (ROIs) were defined using trans-
verse slices at the L3- and L5-levels for both the psoas and paraspinal muscles, with the latter
including the spinotransverse muscles (predominantly multifidus) and erector spinae group
(longissimus and iliocostalis) [20]. For each ROI, several parameters were calculated, as pro-
posed by Fortin and Battie´ [19]. These parameters included the total cross-sectional area
(CSA) and functional cross-sectional area (FCSA), with the latter providing a measure of the
remaining functional tissue in the respective muscles. In summary, FCSA measurements are
governed by a thresholding method in which the upper limit for mean muscle tissue signal
intensity is defined by the reader. Fat fraction was defined by the equation FF = 1 –FCSA/CSA
(Fig 1). Resulting values ranged from 0 (no degeneration) to 1 (complete fatty degeneration).
The total time required for these evaluations was approximately 10 minutes per case. For the
assessment of the follow-up examinations, mean values of FF (including left- and right-sided
ROIs at the L3- and L5-levels) were calculated for the psoas and paraspinal muscles.
Clinical examinations
An assessment of clinical severity was made on the day of the MRI examination. Several tests
were performed: a 6-minute walk test [21]; the 4-step stair climb test [22]; spirometry, with
assessment of the forced vital capacity (in the sitting and supine positions); and strength tests
of the paraspinal and psoas muscles [23]. This latter test used the Medical Research Council
(MRC) scale for muscle strength (only full grades were used), with the psoas muscle tested
bilaterally, and the lower score taken if discordant. Laboratory tests included levels of plasma
creatine kinase (CK).
Statistics
Inter-observer agreement for Mercuri scores was assessed using linear-weighted kappa (κ). A
κ coefficient of>0.6–0.8 indicated good agreement, with an almost perfect agreement indi-
cated by a κ of between 0.81 and 1. Inter-observer agreement for FF was assessed using the
two-way mixed single-measure intra-class correlation coefficient (ICC). ICCs of> 0.75
or> 0.9 indicated a good and excellent agreement, respectively [24]. Correlations between
Mercuri scores and clinical parameters were tested for significance using the Kruskal-Wallis
test. Correlations between Mercuri scores, as well as FF and clinical parameters were quanti-
fied by Spearman’s correlation coefficient (ρ). Differences in clinical and MR-parameters
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during follow-up were tested for significance by applying the Wilcoxon-test. A P value< 0.05
was considered significant in all statistical analyses, which were exploratory; no adjustments of
P values for multiple tests were performed, and the presented P values therefore are descrip-
tive. All data analyses were carried out with SPSS Statistics (version 23.0, IBM, Ehningen,
Germany).
Results
MRI and inter-observer agreement
The initial MRI examinations could be analyzed in all 41 patients. Mercuri scores as assessed
by the two observers are shown in Table 1. Inter-observer agreement for Mercuri scoring was
good, both for the psoas (κ = 0.89 [95% confidence interval 0.81–0.97]) and paraspinal muscles
(κ = 0.85 [95% confidence interval 0.76–0.94]).
Mean FFs of the psoas muscle, as assessed by observer 1, were 0.37 (± 0.35) at the L3-level,
and 0.35 (± 0.37) at the L5-level (P = 0.515).Means for FFs of the paraspinal muscles were 0.42
(± 0.38) at the L3-level, and 0.43 (± 0.35) at the L5-level (P = 0.617).
Mean FFs of the psoas muscle, as assessed by observer 2, were 0.34 (± 0.37) at the L3-level,
and 0.37 (± 0.39) at the L5-level (P = 0.277). Means for FFs of the paraspinal muscles were 0.47
(± 0.4) at the L3-level, and 0.49 (± 0.36) at the L5-level (P = 0.124).
FF correlated well with Mercuri scores, although some overlap of quantitative data was seen
for adjacent Mercuri scores (Fig 2).
Inter-observer agreement was high for the semi-automated method with ICCs indicating
an almost perfect agreement. Inter-observer differences mainly occurred with a depiction of
the relatively small cross-sectional areas of the psoas muscle at the L3-level (Table 2).
Fig 1. MR-derived measurement of the fat fraction. A region of interest is selected from a T1-weighted TSE sequence
in the left paraspinal musculature at the L3-level (panel a). Fat fraction is calculated using the equation FF = 1 –FCSA/
CSA; a signal intensity threshold of 772 (derived from normal muscle–the medial multifidus muscle in this case)
segregates muscle from fat tissue. Pixels beneath this threshold, colored red (panel b), constitute the FCSA (1096 mm2),
while the entire area of the ROI constitutes the CSA (1466 mm2). These data result in an FF value of 0.25.
https://doi.org/10.1371/journal.pone.0190784.g001
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Correlates between MRI and clinical data
Mercuri scores (with categories 2 and 3 combined because of low abundance) for both observ-
ers correlated well with clinical parameters, especially for the 6-minute walk test, forced vital
capacity in the supine position, and MRC scores (Table 3). Plasma CK levels were significantly
lower in patients with a very high degree of fatty muscle degeneration (Mercuri score 4) com-
pared to low to intermediate degeneration (Mercuri scores 1–3, Table 3). Correlations between
Mercuri scores, and MR-derived FF and clinical data are also shown in Table 3. For most of
the assessed clinical tests, correlation coefficients with the FFs were slightly higher compared
to correlation coefficients with the Mercuri scores.
Follow-up under ERT
Clinical data and MR-derived FF values obtained during follow-up are presented in Table 4. A
significant decrease in the performance on the 6-minute walk test and 4-step stair climb test
Table 1. Inter-observer agreement of the Mercuri scores in the psoas and paraspinal muscles.
psoas muscle observer 2
M1 M2 M3 M4
observer 1 M1 20 0 0 0
M2 1 4 2 0
M3 0 1 2 2
M4 0 0 0 9
paraspinal muscles observer 2
M1 M2 M3 M4
observer 1 M1 14 0 0 0
M2 5 2 1 0
M3 0 0 2 3
M4 0 0 0 14
Numbers indicate the total number of patients assigned to the respective Mercuri score (M1-M4) by both observers.
https://doi.org/10.1371/journal.pone.0190784.t001
Fig 2. Representative correlates between the Mercuri scores for paraspinal muscle and FF. Data derived from
observer 1 at the L5-level, Spearman’s ρ = 0.92, P< 0.001.
https://doi.org/10.1371/journal.pone.0190784.g002
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was found between baseline and follow-up 1, with no further decrease between follow-up 1
and follow-up 2. A significant decrease in plasma creatine kinase was also shown during
Table 2. Inter-observer agreement concerning quantitative MR-derived data.
Localization CSA FCSA FF
psoas L3 right 0.617 [0.388–0.775] 0.742 [0.565–0.853] 0.931 [0.876–0.963]
psoas L3 left 0.761 [0.593–0.865] 0.843 [0.725–0.913] 0.933 [0.878–0.964]
paraspinal L3 right 0.895 [0.813–0.943] 0.959 [0.887–0.982] 0.968 [0.898–0.986]
paraspinal L3 left 0.875 [0.778–0.931] 0.959 [0.892–0.982] 0.971 [0.925–0.987]
psoas L5 right 0.914 [0.846–0.953] 0.964 [0.964–0.98] 0.97 [0.944–0.984]
psoas L5 left 0.832 [0.706–0.906] 0.919 [0.854–0.956] 0.96 [0.927–0.979]
paraspinal L5 right 0.823 [0.428–0.929] 0.923 [0.526–0.975] 0.953 [0.822–0.981]
paraspinal L5 left 0.874 [0.72–0.939] 0.937 [0.694–0.977] 0.954 [0.82–0.981]
total average 0.824 [0.659–0.905] 0.906 [0.763–0.952] 0.955 [0.886–0.978]
Two-way mixed single-measure intra-class correlation coefficients (ICC) with 95% confidence intervals for CSA,
FCSA, and fat fraction (FF = 1-FCSA/CSA) are given, P value is < 0.001 for all coefficients.
CSA = cross-sectional area
FCSA = functional cross-sectional area
https://doi.org/10.1371/journal.pone.0190784.t002
Table 3. Correlations between MR-derived data and clinical parameters.
6-minute walk test
(n = 39)
4-step stair climb test
(n = 36)
FVC sitting
(n = 40)
FVC supine
(n = 40)
creatine kinase
(n = 41)
MRC score
(n = 40)
psoas muscle
Mercuri 1 535 m 2.1 sec 3.2 l 3 l 786 U/l 5
Mercuri 2/3 473 m 3 sec 3.2 l 2.7 l 895 U/l 3
Mercuri 4 332 m 3.7 sec 2.4 l 1.4 l 405 U/l 2
P value 0.049 0.066 0.172 0.006 0.114 <0.001
paraspinal muscles
Mercuri 1 583 m 2.1 sec 3.1 l 3 l 993 U/l 5
Mercuri 2/3 411 m 2.5 sec 3.3 l 2.4 l 892 U/l 4
Mercuri 4 371 m 3.3 sec 2.6 l 2.2 l 388 U/l 4
P value 0.025 0.064 0.387 0.068 0.007 0.004
psoas muscle
ρ with Mercuri (P
value)
-0.4 (0.012) 0.39 (0.018) -0.3 (0.062) -0.52 (0.001) -0.28 (0.079) -0.68 (<0.001)
ρ with FF L3 (P value) -0.42 (0.008) 0.43 (0.009) -0.35 (0.027) -0.56 (<0.001) -0.19 (0.226) -0.59 (<0.001)
ρ with FF L5 (P value) -0.48 (0.002) 0.51 (0.002) -0.37 (0.019) -0.56 (<0.001) -0.26 (0.103) -0.63 (<0.001)
paraspinal muscles
ρ with Mercuri (P
value)
-0.4 (0.012) 0.37 (0.025) -0.2 (0.22) -0.37 (0.019) -0.35 (0.023) -0.57 (<0.001)
ρ with FF L3 (P value) -0.52 (0.001) 0.45 (0.006) -0.26 (0.1) -0.41 (0.009) -0.31 (0.048) -0.6 (<0.001)
ρ with FF L5 (P value) -0.52 (0.001) 0.5 (0.002) -0.36 (0.022) -0.5 (0.001) -0.28 (0.032) -0.61 (<0.001)
Median values of the clinical tests depending on the Mercuri scores of the psoas and paraspinal muscles are presented. P values are the result of applying the Kruskal-
Wallis test. Additionally, correlations between the Mercuri scores as well as FFs at the L3- and L5-levels with clinical data are described by Spearman correlation
coefficients (ρ). Data result from observer 1 (corresponding data as assessed by observer 2 can be derived from S1 Dataset).
FVC = forced vital capacity
MRC = Medical Research Council
https://doi.org/10.1371/journal.pone.0190784.t003
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follow-up. Corresponding to these clinical findings, the MR-derived FF of the psoas muscle
increased significantly between baseline and follow-up 1, with no statistically significant
change between follow-up 1 and follow-up 2 (Table 4).
Additionally, one patient who did not receive enzyme replacement therapy because of age
(70 years at the time of initial diagnosis) was followed-up yearly to demonstrate the value of
the proposed quantification method. In this patient, the psoas muscle was already completely
degenerated at the initial presentation, but the FF of the paraspinal muscle had increased line-
arly from 0.38 at baseline to 0.74 at 5 years (Fig 3).
Discussion
In our study, we evaluated a simple method to quantify muscular degeneration and replace-
ment by fat based on commonly used (turbo) spin echo MR-sequences. This method, previ-
ously used for degenerative spine diseases like symptomatic disc herniation with lower back
pain [25], was applied on a large collective of patients with LOPD, using conventional
Table 4. Changes of clinical and MR-derived data during follow-up.
Group 1—all patients
(n = 13)
Group 2—patients who participated in FU2
(n = 7)
baseline FU1 vs.
baseline
baseline FU1 vs. baseline FU2 vs.
baseline x
FU2 vs. FU1 x
6MWT [m]
P value
503 ± 126 -53 ± 46
0.006
508 ± 133 -59 ± 54
0.043
-40 ± 82c
0.345
6 ± 25
0.893
4-step [s]
P value
3.1 ± 2.4a 1.2 ± 2.2
0.034
3.5 ± 3.3b 1.4 ± 2.8b
0.075
0.4 ± 0.7c
0.465
0.2 ± 0.7c
0.715
FVCsit [l]
P value
2.9 ± 0.7 0.2 ± 0.6
0.328
2.7 ± 0.7 0.3 ± 0.6
0.398
0.1 ± 1.1
1.0
-0.2 ± 0.7
0.31
FVCsup [l]
P value
2.5 ± 0.7 0.1 ± 0.8
0.972
2.5 ± 0.6 0.2 ± 0.7
0.735
0.1 ± 1
0.31
-0.1 ± 0.5
0.31
CK [U/l]
P value
785 ± 273 -209 ± 224
0.016
848 ± 215 -359 ± 161
0.018
-424 ± 186
0.018
-65 ± 70
0.063
FFpsoas
P value
0.36 ± 0.37 0.05 ± 0.09
0.016
0.23 ± 0.24 0.04 ± 0.06
0.091
0.1 ± 0.14
0.063
0.06 ± 0.14
0.499
FFpara
P value
0.56 ± 0.39 0.03 ± 0.1
0.753
0.47 ± 0.41 0.06 ± 0.14
0.866
0 ± 0.08
0.735
-0.06 ± 0.1
0.176
Mercuripsoas
P value
2.1 ± 1.3 0.2 ± 0.4
0.083
1.6 ± 0.8 0.3 ± 0.5
0.157
0.6 ± 0.8
0.102
0.3 ± 0.5
0.157
Mercuripara
P value
2.7 ± 1.4 0.2 ± 0.4
0.083
2.3 ± 1.4 0.4 ± 0.5
0.083
0.4 ± 0.5
0.083
0 ± 0
1.0
Baseline values and changes versus the baseline (described as mean ± standard deviation) are shown for patients with one (group 1), and two (group 2) follow-up MR
examinations, respectively.
a n = 12
b n = 6
c n = 5
FU = follow-up
6MWT = six-minute walk test
4-step = Four-step stair climb test
FVCsit = forced vital capacity in the sitting position
FVCsup = forced vital capacity in the supine position
CK = creatine kinase
FFpsoas = MR-derived fat fraction of the psoas muscle
FFpara = MR-derived fat fraction of the paraspinal muscles
https://doi.org/10.1371/journal.pone.0190784.t004
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T1-weighted images. A high inter-observer agreement, in addition to previously reported high
intra-observer reliability [19,26], as well as good correlations with clinical data were demon-
strated. This simple type of measurement would easily translate to the clinic, with the added
advantage that, compared to Mercuri scoring, the relatively wide intervals of FFs in a given
Mercuri score are expressed with a percentage-based and therefore more precise scale (Fig 2).
A literature review revealed inconsistency about whether T1- or T2-weighted images are
preferred when assessing fatty muscle degeneration by conventional MR sequences. While the
majority of authors prefer T1-weighted sequences [13,17,27,28], others have used T2-weighted
images [19,25]. T2-weighted imaging risks overestimating fatty muscle degeneration because
fat, edema, and high glycogen content appear hyperintense; thus, T1-weighted images would
be preferable to monitor Pompe disease. Differences in FF between the L3- and L5-levels were
very low in absolute numbers. These results suggest that the mean value of several slices cover-
ing the whole muscle volume should be calculated to generate an overall score.
The main technical limitation when using TSE sequences for fat detection is the presence of
field inhomogeneity causing high signal intensity variation, which aggravates with increasing
field strength and has been reported to be up to 80% at 3 T [29]. Additionally, the method
requires a clear separation of muscle and fat, which is far from being guaranteed in fat infil-
trated muscles, with possibly a large range of voxel FF values.
Fig 3. Fat fraction of the paraspinal muscles during follow-up. Images acquired at baseline (panel a), followed-up yearly (panel b-f) are shown. Fatty
infiltrated muscle is colored red. The fat fraction increased from 0.38 (panel a) via 0.46 (b), 0.53 (c), 0.57 (d), 0.66 (e) to 0.74 (f).
https://doi.org/10.1371/journal.pone.0190784.g003
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Field inhomogeneities account for high differences in the signal intensity of subcutaneous
fat, which was used for reference by Mhuiris et al [18]. This is the main limitation of their
method, especially because the ROIs used in their study were very small. In contrast, the
method used here smoothens field inhomogeneities by the definition of an intra-individual
threshold in the area of interest, and subsequent binary assignment of a single voxel to fat or
muscle.
In recent studies, the quantification of intramuscular fat has been achieved using Dixon
water and fat separation techniques [15,28] or T2-quantification [30]. For example, excellent
inter-observer and retest accuracy in patients with limb girdle muscular dystrophy 2I have
been demonstrated [31]. However, the superiority of Dixon MR-sequences vs. conventional
imaging is offset by their frequent retrospective unavailability in older imaging datasets. Still,
those modern sequences should be used in prospective studies because of their higher accuracy
in the differentiation of water and fat signals, voxel-by-voxel, which is mainly a result of their
higher robustness against B0- and B1-inhomogeneities of the magnetic field [32].
Mercuri scores as well as FF values correlated well in the current study with MRC scores of
muscle strength, agreeing with recent whole-body MRI studies in which MRI parameters were
more sensitive in identifying early and clinically silent changes in the musculature [28,33]. Sig-
nificant correlations between Mercuri scores and functional patient stage have also been pub-
lished [34]. In our study, levels of plasma CK were low in patients with advanced disease
(Mercuri 4), but comparatively high in patients with normal or mild muscle changes, as dem-
onstrated by MRI (Table 3). This pattern confirms that MRI data are advantageous in detect-
ing early changes in the musculature [28] and correlate with the clinical presentation of
patients. Only moderate correlations were found between the Mercuri score or FFs and results
of the clinical tests, indicating that more factors than assessable by lumbar muscle MRI (e.g.,
cardiopulmonary function, training level, and personal patient characteristics such as age and
body weight) contribute to the clinical presentation of LOPD patients.
The main clinical use of our method was to assess long-term follow-up of LOPD patients
under ERT. We found a significant decrease in plasma creatine kinase after ERT initiation.
Clinically, a decrease in performance on the 6-minute walk test and 4-step stair climb test was
demonstrated at follow-up 1 after a median of 39 months, which reached a plateau between
follow-up 1 and follow-up 2 after a median of 63 months. Of interest, a comparable trend was
seen for the MR-derived FF of the psoas, but not for the paraspinal muscles, indicating that
especially the psoas (in addition to limb muscles) should be taken into account when assessing
disease severity in prospective studies. A recent meta-analysis has shown that performance on
the six-minute walk test usually increases after initiation of ERT and stays stable afterwards
[7]. However, follow-up times are short in most included studies (ranging from 3 to 75
months), and only one study had a follow-up of more than 3 years [7,35]. Although it is an
objective clinical test, the 6-minute walk test can involve high performance variability depend-
ing on external or internal conditions [21]. Therefore, other parameters such as those derived
from MRI might increase objectivity to evaluate treatment response. Additionally, compared
with other studies [5,36–38], patients in our study performed better on the 6-minute walk test
at baseline (mean walking distance was 503 m in our study, versus 341 m [37], 332 m [5], 265
m [36], and 246 m [38], respectively), indicating a milder disease severity. This difference
might explain the fact that despite ERT administration, performance deteriorated until follow-
up 1. In addition, an increased performance in the 6-minute walk test can be supported by
physical activity. For example, in the study by Strothotte et al [37], patients with the highest
improvements regularly performed training programs. Participation in a physical training pro-
gram was recommended to all patients included in our study. However, as these programs
were not centrally organized, no data concerning the results of these programs, or frequencies
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of participation were assessed. Slowly increasing fatty muscle degeneration under ERT has also
been demonstrated by Carlier et al [15] using Dixon-based quantification of the FF; however,
long-term results are as yet unavailable. In our study the FF remained constant after an initial
increase, which may support the long-term effectiveness of ERT. However, this conclusion
should be taken with caution, because the study was retrospective and no placebo-controlled
or non-treated group was analyzed. Still, the patient who did not receive ERT showed a much
faster fatty muscle degeneration as depicted by MRI (FF of the paraspinal muscles increased by
19% after 3 years of follow-up) compared with the 13 patients under ERT (mean FF increase at
follow-up 1 was 3%; only 2/13 patients showed an increase of more than 19%). A similar ten-
dency was not significantly depicted by applying the Mercuri score, which was expected, as a
change in this score requires a substantial increase in FF, which is very unusual even in severe
cases. Therefore, the Mercuri score seems to be not as appropriate for monitoring subtle mus-
cle degenerative changes, as also recently shown in a longitudinal study of patients with
LGMD2I [31].
Strengths and limitations
Study limitations include the retrospective design, with examinations performed on multiple
MR scanners with different field strengths, and the fact that the number of patients examined
on a 3 T scanner was low. Because field inhomogeneity increases at 3T and no correction filter
for signal non-uniformity was used, a further validation of the method should be performed in
future studies for 3 T scanners. Still, the main use of the method is the analysis of older imaging
data, and these examinations have been most frequently performed on 1.5 T scanners. Addi-
tionally, the proposed quantification method could not be compared with Dixon-based or
other contemporary quantitative techniques, because these data were not retrospectively avail-
able, and inter-study reliability was not tested. Also, the definition of a threshold for normal
muscle tissue is influenced by the reader and therefore less objective than proton-density or
Dixon imaging. Thus, automated approaches as recently proposed might increase objectivity
in future studies [39]. In addition, the binary separation of every voxel being counted as either
muscle or fat is a weakness of the method, whereas water/fat (Dixon) imaging methods allow
for a precise measurement of the degree of fat infiltration, voxel by voxel [15]. However, semi-
automated quantification of fatty muscular degeneration demonstrated, in particular, high
inter-observer agreement (for a relatively large patient cohort), correlation with clinical data,
ease of use, and a retrospective application to gauge disease progression (superior to Mercuri
scoring). Another limitation is that correlates with clinical data were assessed using imaging
data of lumbar muscles only, but these muscles–though less frequently assessed in the litera-
ture–are of high clinical relevance for LOPD patients, and their degeneration might lead to the
initial clinical symptoms in these patients [40]. In addition, as the proposed methods could be
applied to any specific muscle, the incorporation of upper leg muscle imaging might be of use
in future studies. Finally, for a more detailed analysis, whole muscle volumes could be covered
by using more slices, with the drawback of longer evaluation times.
Conclusions
This retrospective monocentric study confirmed the value of muscle MRI to follow-up LOPD
patients, and validated a simple and rapid method to retrospectively assess fatty muscle degen-
eration based on conventional T1-weighted TSE sequences. The following conclusions could
be drawn:
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• A rapid and simple quantification of fatty muscle degeneration can be achieved using con-
ventional T1-TSE sequences with a high inter-observer agreement.
• This method can be used for a more accurate retrospective longitudinal evaluation of older
imaging data compared with Mercuri scoring, when other sequences are unavailable. For
prospective studies, modern water-/fat- (Dixon-) imaging should be used due to its robust-
ness against B0-/B1- inhomogeneities of the magnetic field and more objective voxel-by-
voxel calculation of the FF.
• MRI-derived muscle-specific data correlate with clinical parameters (6-minute walk test,
forced vital capacity, MRC scores of muscle strength), and may be used to monitor ERT.
• After an initial increase, the FF of the psoas muscle stayed constant during long-term follow-
up under ERT.
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